Published in final edited form as:

J Oral Maxillofac Surg Med Pathol. 2018 January ; 30(1): 50–54. doi:10.1016/j.ajoms.2017.08.007.

Necrotizing fungal gingivitis in a patient with Acute Myelogenous Leukemia: visible yet obscure

Prajwal Boddu¹, Pei-Ling Chen², Priyadharsini Nagarajan², Victor G. Prieto², Alex Won³, Mark Chambers³, and Steven Kornblau¹

¹Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas

²Department of Pathology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas

³Department of Oncologic Dentistry Prosthodontics, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas

Abstract

Oral fungal infections present with atypical and varied manifestations, and distinguishing them from other entities including leukemic infiltration can be diagnostically challenging. In this report, we describe a 62 year old female with acute myeloid leukemia who presented, towards the end of her second treatment cycle of decitabine in a prolonged neutropenic state, with a month of painful, necrotic-appearing marginal gingival lesions. She was duly initiated on empiric broad spectrum antifungal treatment but did not show a clinical response with the appearance of new skin lesions concerning for progressive fungemia. Concurrent gingival and cutaneous biopsy showed fungal invasion with *Fusarium*. Despite changing antifungal treatment the lesions progressed, and white blood cell (WBC) transfusions were instituted. The patient had an impressive response with gradual resolution of the skin lesions and regression in gingival lesions over a week of therapy. This case illustrates the highly atypical, confounding appearance of oral fungal infections in immunocompromised hematological malignancy patients. Maxillary and mandibular marginal gingival involvement, although extremely rare, should be recognized as potential sites of fungal involvement. Accurate diagnosis entails a biopsy especially in ambiguous clinical scenarios, as presented here. The role of WBC transfusions in the management of these rare fungal pathogenic infections needs to be re-established.

Correspondence: Prajwal Boddu, MD, Department of Leukemia, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 448, Houston, TX 77030, Phone: (713)792-5556, pcboddu@mdanderson.org.

Ethical approval- Was reviewed by MDACC IRB review board, and determined that it is not human subjects research and does not require IRB approval

Conflicts of Interests - The authors report no competing conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Fusarium; fungal; gingival; acute myelogenous leukemia; neutropenia

1. INTRODUCTION

The incidence of opportunistic invasive fungal infections among the general population has increased significantly over the past two decades [1–3]. This is primarily related to a growing number of at-risk immunocompromised patients with AIDS, advanced malignancies, longstanding diabetes mellitus, and recipients of bone marrow and solid organ transplants, on long-term immunosuppressive therapies [4]. It has long been known that immunosuppression provides a haven for normally avirulent opportunistic pathogens like *Candida*, *Aspergillus*, *Rhizopus* and *Fusarium* to proliferate and disseminate, causing potentially life threatening fungal infections. While the majority of fungal infections continue to be attributed to *Aspergillus* and *Candida*, the pathogenic spectrum is expanding with infections from a variety of rare opportunistic pathogens, especially rare mold species, becoming more common [5, 6]. Various factors including more intense immunosuppression with novel agents and steroid-sparing regimens, selective pressures from anti-fungal prophylaxis practices, prolonged survival beyond expectancy of previously fatal diseases and improved laboratory identification techniques, among others have been cited as important factors behind this changing epidemiology [7, 8]. While the fluctuating spectrum of fungal pathogens has resulted in a concurrent increase in the development of newer, expanded spectrum agents such as voriconazole and posaconazole, some of these rare pathogens remain poorly responsive also to several of the newer agents.

The true incidence of stomatologic fungal infections in the immunocompromised population is not clearly known, but is estimated to be very low, with the most common cause being *Candida* species [9]. Oral localization may be primary (by oral pathogens such as *Aspergillus* species, zygomycetes) or secondary to systemic fungal disease. Pertinently, apart from the commonly implicated pathogens such *Candida* and *Aspergillus*, infection with the normally avirulent, saprophytic fungi including *Geotrichum*, *Fusarium*, *Rhodotorula*, *Saccharomyces* and *Penicillium* species are being increasingly identified as oral pathogens, with significant implications in choice of therapy and prognosis [10].

A clinical conundrum is being able to distinguish disseminated fungal infections from leukemia cutis. Both entities have similar clinical presentations and may temporally co-occur in the same patient, rarely occurring at the same location [11]. Therefore, confirmation requires a histological examination. In this report, we describe a case of acute myelogenous leukemia (AML) complicated by necrotic gingival and cutaneous lesions, which were later attributed to be fungal in etiology.

2. CASE REPORT

A 62 year-old female with a history of myelodysplastic syndrome (MDS) transformed to AML was admitted with shortness of breath after receiving two units of red blood cell (RBC) transfusion. She was first diagnosed with MDS 2 years previously when she was

found to be pancytopenic during a pre-operative evaluation for elective knee repair. She remained transfusion independent and was observed for her MDS, until 3 months prior, when she had a repeat bone marrow evaluation for worsening cytopenia. Bone marrow revealed leukemic transformation with 51% myeloid blasts and mutations in *TP53*, *NRAS*, *NOTCH*, *TET2*, and complex cytogenetics. She was then induced with cladribine, idarubicin, cytarabine (CLIA). She did not respond to CLIA and was transitioned to a 10-day decitabine regimen. She was admitted 30 days into her second cycle of decitabine, with continued severe neutropenia since completing her first decitabine course.

On admission, she reported gingival pain and oral lesions which were first noticed a month prior to admission. The patient had developed sublingual ulcerations two weeks prior to admission, typical of those arising from chemotherapy began 4 weeks prior to admission. Upon admission she reported that the original lesions had largely resolved, but that she now had new lesions along the anterior gingival-dentition margins near both the upper and lower incisors. Of note, the patient had undergone numerous prior dental restorations such as fixed bridges and crowns on the anterior mandible. The lesions appeared necrotic with yellow-white tinted tissue along the buccal-facing gingival tissue at the base of her upper and lower incisors, and in the premaxillary region nearest the interincisal papillae. There was also gingival hyperplasia adjacent to these regions. Laboratory findings on admission included profound trilineage pancytopenia (table 1). A maxillofacial CT scan was performed and showed fat stranding over the anterior mandibular buccal gingiva, and a bony defect immediately adjacent to it concerning for osteomyelitis (Figure 1). A biopsy was requested, to help distinguish between infection and leukemic infiltrate, but was not performed due to concerns about bleeding from the patient's profound thrombocytopenia. She was started promptly on empiric broad spectrum antimicrobials, including antifungal coverage with caspofungin and posaconazole. Unfortunately, her oral lesions continued to progress very slowly over the next ten days despite continued antimicrobial therapy and oral rinses with keratinocyte growth factor support. Attempts at improving absolute neutrophil (ANC) counts with filgrastim proved unsuccessful. Approximately 10 days into admission she developed new skin lesions on her forehead and shoulders, raising a concern for disseminated fungemia versus leukemia cutis. Pathology of the oral tissue, sampled 23 days post admission, showed necrotic gingival tissue with numerous septate hyphae staining positive for GMS stain (Figure 2). A concurrent skin biopsy also demonstrated GMS positive angioinvasive septate organisms with constricted hyphae and dilated chlamydoconidia morphologically raising the possibility of *Fusarium sp* (Figure 3). Additionally, chest imaging showed multiple nodular pulmonary lesions suspicious for multifocal fungal infection. Antifungals were expanded to include intravenous liposomal amphotericin, voriconazole and posaconazole for better *Aspergillus* and *Fusarium* coverage and white blood cell (WBC) transfusions were begun to help improve her WBC counts against the infection. A week after collection the skin biopsy tissue culture grew *Fusarium* species. Due to limited tissue material, the oral tissue biopsy was not sent for culture. Nevertheless, she showed an impressive improvement in her oral and skin lesions a week into receiving 3 sessions of WBC transfusions along with antifungal therapy. Unfortunately, two weeks into therapy, the patient developed sudden onset of shortness of breath which progressed to fatal hypoxic respiratory failure. Autopsy was not performed.

3. DISCUSSION

Fusarium species typically cause superficial skin infections in immunocompetent patients but may present as disseminated infections, especially in the immunocompromised, hematological malignancy population [12, 13]. After *Aspergillus*, *Fusarium* is the second most common cause of invasive mold infections in immunocompromised patients [10, 14]. Main portals of entry for this pathogen include the skin and the sino-pulmonary tree [13]. Risk factors for *Fusarium* include persistent granulocytopenia, T-cell lymphocyte depletion and previous fungal infections [15]. Oral invasive *Fusarium* infection has only rarely been described to occur as a necrotic gingival ulceration extending into the alveolar bone in a neutropenic patient [16]. More often, the infection is limited to the sinuses and does not involve an oral element [17]. Two important characteristics consistent with diagnosis of *Fusarium* infection include the blood cultures growing mold and the presence of skin lesions [13]. While none of the blood cultures grew mold, our patient had multiple skin lesions with a positive skin biopsy culture strongly supportive of *Fusarium* infection. Because the narrow, dichotomously branching, septate hyphae of *Fusarium* share morphological similarities with other fungi including *Aspergillus* and *Scedosporium*, differentiation often requires immunohistochemistry [18] and special in-situ hybridization techniques to be performed on paraffin-embedded tissue specimens [19, 20] or microbiology culture. These techniques are especially useful when the cultures for identifying the mold return negative. Of note, beta-glucan assays are not specific for *Fusarium*, and *Aspergillus* galactomannan assays cross-react with *Fusarium* [21, 22]. Therapy should be instituted promptly based on supportive findings since species identification is often not available immediately.

Distinguishing gingival fungal infection clinically from gingival leukemic infiltration can be challenging. Gingival leukemia generally presents with erythematous or cyanotic gingival hyperplasia with or without necrosis, petechiae, ulcers, and hemorrhage and is more common in the acute myelomonocytic leukemia [23, 24]. Our patient did have focal areas of sharply demarcated, necrotic appearing lesions with surrounding gingival hyperplasia with CT image findings concerning for leukemic infiltration.

Invasive *Fusarium* infection is associated with a very poor prognosis and outcomes are heavily dependent upon immune system recovery. Therapy entails prompt institution of systemic broad-spectrum antifungal therapy. Combination therapies including the lipid formulation of amphotericin B and voriconazole are preferred over monotherapy, especially in patients who are severely immunocompromised or with severe fungal disease, due of the variable susceptibility of *Fusarium* species to antifungal agents [25]. Successful outcomes have been reported with other azole agents such as posaconazole, isavuconazole [26, 27]. Surgical debridement of infected tissues, although ideal when performed early, carries the risk of bleeding from accompanying thrombocytopenia, such as in our patient. Adjunctive therapies such as G-CSF and white blood cell transfusions have long been used to enhance immune system recovery, but their efficacy in *Fusarium* infections has not been established [28, 29]. A recent systematic review did not find a difference in the clinical reversal of infection between patients receiving white cell transfusion support and those who did not [30]. However, this study was not focused on fungal infections. In contrast, another single center study investigating the role of granulocyte transfusions found that donor-stimulated

granulocyte transfusions contributed to higher response rates but only in patients who had a good neutrophil recovery and not in the absence, thereof [31]. WBC transfusions should be instituted early in management if prolonged neutropenia is anticipated. Our patient had an impressive response to granulocyte transfusions effectively bridging her period of neutropenia whilst she was treated on broad-spectrum antifungals. The patient's death was a sudden, unexpected event in the course of gradually improvement.

Fusarium is a component of the normal oral mycobiome in upto 30% of healthy individuals [32]. It is possible that the pathogenicity of the fungus is controlled by other components of the mycobiome and by a functional immune system, unlike in the case of immunocompromised patients. Various systemic (immunosuppression, age, nutritional and dietary status) and local (salivary flow, dentures and associated base material, and cleanliness) factors influence the severity and duration of fungal stomatitis [9, 33, 34]. Marginal gingiva has been cited as portal of entry for fungal spores [35]. While dental restorations, per se, have not been implicated as foci of infection, biofilm formations still remain a concern despite biomaterial modifications, and poorly contoured restorations can certainly trap debris and promote plaque formation [36]. Our patient had had multiple prior dental restorations leading to plaque accumulation, which along with poor oral hygiene, might have been major contributing factors towards causing gingival invasion. Marginal gingivitis has been associated with plaque formation consequent to the presence of restorative materials on tooth surfaces [37]. This may explain the involvement of the gingival margins, an unusual manifestation of oral fungal infection which more frequently involves the palate and sinuses [9, 38].

This case illustrates the highly atypical, confounding appearance of fungal stomatitis in immunocompromised patients with hematological malignancies. Maxillary and mandibular marginal gingival involvement, although extremely rare, should also be recognized as potential sites of fungal involvement and evaluated for the same. Accurate diagnosis entails a biopsy especially in ambiguous clinical settings such as in the current scenario. Morphologic features may suggest the diagnosis of *Fusarium*, *Aspergillus* or *Scedpsporium sp.*, and immunohistochemical analysis and/or tissue cultures will be needed to confirm the morphologic impression.

Acknowledgments

Our funding was from the following sources - Supported in part by the MD Anderson Cancer Center Support Grant CA016672 (PI: Dr. Ronald DePinho) and Award Number P01 CA049639

References

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis.* 2004; 39(3):309–317. [PubMed: 15306996]
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis.* 2002; 34(7):909–917. [PubMed: 11880955]
3. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. *Clin Infect Dis.* 2001; 32(9):1319–1324. [PubMed: 11303267]

4. MAP. Invasive fungal pathogens: Current epidemiological trends. *Clin Infect Dis* 2006. 2006; 43:S3–14.
5. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. *Clin Infect Dis*. 2001; 33(10):1692–1696. [PubMed: 11641825]
6. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. *Drugs*. 2007; 67(13):1803–1812. [PubMed: 17722951]
7. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. *Clin Microbiol Infect*. 2008; 14(Suppl 4):5–24.
8. Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, Bucker V, Wisplinghoff H, Scheid C, Cornely OA, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. *J Antimicrob Chemother*. 2016; 71(9):2634–2641. [PubMed: 27317443]
9. Iatta R, Napoli C, Borghi E, Montagna MT. Rare mycoses of the oral cavity: a literature epidemiologic review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2009; 108(5):647–655. [PubMed: 19836721]
10. Deepa A, Nair BJ, Sivakumar T, Joseph AP. Uncommon opportunistic fungal infections of oral cavity: A review. *J Oral Maxillofac Pathol*. 2014; 18(2):235–243. [PubMed: 25328305]
11. Chang YC, Stewart C, Chu EY, Rosenbach M. Rare angioinvasive fungal infection in association with leukemia cutis. *Cutis*. 2015; 95(6):332–335. [PubMed: 26125209]
12. Nucci M, Anaissie E. Cutaneous infection by *Fusarium* species in healthy and immunocompromised hosts: implications for diagnosis and management. *Clin Infect Dis*. 2002; 35(8):909–920. [PubMed: 12355377]
13. Boutati EI, Anaissie EJ. *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. *Blood*. 1997; 90(3):999–1008. [PubMed: 9242529]
14. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. *Transpl Infect Dis*. 1999; 1(4):247–261. [PubMed: 11428996]
15. Huprikar S, Shoham S. Practice ASTIDCo: Emerging fungal infections in solid organ transplantation. *Am J Transplant*. 2013; 13(Suppl 4):262–271. [PubMed: 23465019]
16. Myoken Y, Sugata T, Kyo T, Fujihara M. Oral *Fusarium* infection in a granulocytopenic patient with acute myelogenous leukemia: a case report. *J Oral Pathol Med*. 1995; 24(5):237–240. [PubMed: 7616464]
17. Chambers MS, Lyzak WA, Martin JW, Lyzak JS, Toth BB. Oral complications associated with aspergillosis in patients with a hematologic malignancy. Presentation and treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1995; 79(5):559–563. [PubMed: 7600217]
18. Jensen, HEAB., Jungersen, Gregers, Hartvig, T., Moser, C., Rozell, BL., Blennow, O. Immunohistochemical diagnosis of fusariosis with monoclonal antibodies. 5th Congress on Trends in Medical Mycology; Valencia, Spain. 2011.
19. Hayden RT, Isotalo PA, Parrett T, Wolk DM, Qian X, Roberts GD, et al. In situ hybridization for the differentiation of *Aspergillus*, *Fusarium*, and *Pseudallescheria* species in tissue section. *Diagn Mol Pathol*. 2003; 12(1):21–26. [PubMed: 12605032]
20. Montone KT. Differentiation of *Fusarium* from *Aspergillus* species by colorimetric in situ hybridization in formalin-fixed, paraffin-embedded tissue sections using dual fluorogenic-labeled LNA probes. *Am J Clin Pathol*. 2009; 132(6):866–870. [PubMed: 19926577]
21. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis*. 2004; 39(2):199–205. [PubMed: 15307029]
22. Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, Cavanna C, Cascio GL. Cross-reactivity of *Fusarium* spp. in the *Aspergillus* Galactomannan enzyme-linked immunosorbent assay. *J Clin Microbiol*. 2012; 50(3):1051–1053. [PubMed: 22205818]
23. Menezes L, Rao JR. Acute myelomonocytic leukemia presenting with gingival enlargement as the only clinical manifestation. *J Indian Soc Periodontol*. 2012; 16(4):597–601. [PubMed: 23493961]

24. Bressman E, Decter JA, Chasens AI, Sackler RS. Acute myeloblastic leukemia with oral manifestations. Report of a case. *Oral Surg Oral Med Oral Pathol.* 1982; 54(4):401–403. [PubMed: 6959054]
25. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. *N Engl J Med.* 2014; 371(2):150–160. [PubMed: 25006721]
26. Slavin MA, Thursky KA. Isavuconazole: a role for the newest broad-spectrum triazole. *Lancet.* 2016; 387(10020):726–728. [PubMed: 26684608]
27. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. *Clin Infect Dis.* 2006; 42(10):1398–1403. [PubMed: 16619151]
28. Hennequin C, Benkerrou M, Gaillard JL, Blanche S, Fraitag S. Role of granulocyte colony-stimulating factor in the management of infection with *Fusarium oxysporum* in a neutropenic child. *Clin Infect Dis.* 1994; 18(3):490–491. [PubMed: 7516720]
29. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. *Leukemia.* 1997; 11(10):1621–1630. [PubMed: 9324280]
30. Estcourt LJSS, Hopewell S, Doree C, Trivella M, Massey E. Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. *Cochrane Database of Systematic Reviews.* 2016; (4)
31. Kadri SS, Remy KE, Strich JR, Gea-Banacloche J, Leitman SF. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. *Transfusion.* 2015; 55(9): 2076–2085. [PubMed: 25857209]
32. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A, Gillevet PM. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog.* 2010; 6(1):e1000713. [PubMed: 20072605]
33. Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview. *Oral Dis.* 2005; 11(5):268–273. [PubMed: 16120112]
34. Kantarcioglu AS, Gulenc M, Yucel A, Uzun N, Taskin T, Sakiz D, Altas K. Cryptococcal parotid involvement: an uncommon localization of *Cryptococcus neoformans*. *Med Mycol.* 2006; 44(3): 279–283. [PubMed: 16702109]
35. Neville, BWDD., Allen, CM., Bouquot, JE. Oral and maxillofacial pathology. 3. WB Saunder; 2009. p. 224-237.
36. Busscher HJ, Rinastiti M, Siswomihardjo W, van der Mei HC. Biofilm formation on dental restorative and implant materials. *J Dent Res.* 2010; 89(7):657–665. [PubMed: 20448246]
37. Litonjua LA, Cabanilla LL, Abbott LJ. Plaque formation and marginal gingivitis associated with restorative materials. *Compend Contin Educ Dent.* 2012; 33(1):e6–10. [PubMed: 23268568]
38. Krishnan PA. Fungal infections of the oral mucosa. *Indian J Dent Res.* 2012; 23(5):650–659. [PubMed: 23422613]

Figure 1. Maxillofacial CT scan: A) Study challenged by dental artifact but fat stranding and abnormal enhancement over the anterior mandibular buccal gingiva enclosed in dotted black circle. B) Adjacent bony defect with possible loss of cortical bone in white circle

Figure 2.

A) Necrotic pre-mandibular gingival tissue (day 22, post-admit) before treatment with antifungals and white blood cell transfusions, B) Post-WBC transfusion treatment (day 7) photographic image after expulsion of necrotic tissue exposing underlying dental implants. C) Low power view showing pink acellular necrotic tissue with hyphae in the underlying oral mucosa (x 40). D) Higher power view demonstrating septate fungal hyphae within the squamous tissue (x 20).

Figure 3.

A) Papulo-nodular violaceous forehead skin lesion with an overlying suture placed after a punch biopsy, B) Subcutaneous tissue with H & E staining highlighting angioinvasive fungal organisms (x 60). C) Counterstaining with Giemsa highlighting angioinvasive fungal organisms (x 60).

Table 1

Peripheral blood counts over the course of hospital stay

Day	WBC (x 10 ⁹ /L)	ANC (x 10 ⁹ /L)	Hemoglobin (gm/dL)	Platelet (x 10 ⁹ /L)
0 (admission date)	0.0	0.0	10.9	19
10 (skin lesions)	0.0	0.0	9.8	4
14 (Day of 1 st WBC transfusion)	0.7	0.2	12.3	46
22 (after 2 transfusions)	2.7	2.7	8.0	38